指南与共识血栓与止血

2025年ASH ISTH NBDF WFH关于2021年血管性血友病诊断与管理临床指南的监测报告

2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease.
指南 / 共识 · Blood Adv · 2025-01-01

美国血液学会(ASH)、国际血栓与止血学会(ISTH)、国家血友病基金会(NHF;现为全国出血性疾病基金会)和世界血友病联盟(WFH)2021年血管性血友病(VWD)诊断与管理指南包含诊断推荐11条和管理推荐12条。本文报告指南临床联合主席受ASH要求对2021年指南进行审查的结果,以判断是否需要修订及修订时机。更新检索后,诊断方面17篇、管理方面37篇文献进入全文审查,未发现可改变现有推荐方向或强度的研究。

要点

  • 2021年ASH ISTH NHF WFH的VWD指南含诊断推荐11条、管理推荐12条。
  • 更新检索后诊断17篇、管理37篇文献进入全文审查。
  • 审查未发现可改变现有推荐方向或强度的研究。

核心结论

  • 基于审查,临床联合主席指出所审查的研究均不会改变现有指南推荐的方向或强度。
  • 将继续监测2021年指南,以评估是否有足够新证据值得进一步修订。

研究设计与样本

  • ASH要求指南临床联合主席对2021年指南进行审查,以判断是否需要修订及修订时机。
  • 更新MEDLINE和Embase检索,采用与2021年指南相同的检索词,诊断文献限2020年至2024年7月30日,管理文献限2020年至2024年7月24日。
  • 诊断方面识别432项研究,17篇进入全文审查;管理方面识别288项研究,37篇进入全文审查。

主要发现

  • 诊断方面432项研究经标题摘要审查,17篇进入全文审查。
  • 管理方面288项研究经标题摘要审查,37篇进入全文审查。
  • 审查旨在判断数据是否改变现有推荐的方向或强度,或值得制定新推荐。
  • 临床联合主席指出所审查的研究均不会改变现有指南推荐的方向或强度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF; now National Bleeding Disorders Foundation), and World Federation of Hemophilia (WFH) 2021 guidelines on the diagnosis and management of von Willebrand disease (VWD) included 11 recommendations on the diagnosis of VWD and 12 recommendations on the management of VWD, the most common inherited bleeding disorder. We describe the results of a review of the 2021 guidelines by the clinical co-chairs of the guideline panels requested by ASH to inform decision-making about the need for and timing of a guideline revision. An updated MEDLINE and Embase search applied the same terms as the ASH ISTH NHF WFH 2021 guidelines limited to studies from 2020 to 30 July 2024 (diagnosis) or 24 July 2024 (management). For the diagnosis of VWD, 432 studies were identified and underwent title and abstract review, with 17 undergoing full text review, and for the management of VWD, 288 studies were identified and underwent title and abstract review, with 37 undergoing full text review, to determine whether the data would change the strength or directionality of the existing recommendation or merit development of a new recommendation. Based on this review, the clinical co-chairs noted that none of the reviewed studies would change the direction or strength of the existing guideline recommendations. There will be continued monitoring of the ASH ISTH NHF WFH 2021 guidelines on the diagnosis and management of VWD to evaluate whether there is sufficient new evidence to warrant additional revisions.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. James PD, Flood VH, Connell NT, et al. 2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease. Blood Adv. 2025. PMID: 40273329. doi:10.1182/bloodadvances.2025016512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。